Picture of Venture Life logo

VLG Venture Life News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

REG - Venture Life Group - Investor Presentation via Investor Meet Company

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230905:nRSE3149La&default-theme=true

RNS Number : 3149L  Venture Life Group PLC  05 September 2023

5 September 2023

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Investor Presentation via Investor Meet Company

 

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, is pleased to announce that
Jerry Randall (CEO) and Daniel Wells (CFO) will provide a live presentation
relating to the 2023 Interim Results via Investor Meet Company on 27
September 2023 at 11:00am BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet
Venture Life Group plc via:

https://www.investormeetcompany.com/venture-life-group-plc/register-investor
(https://www.investormeetcompany.com/venture-life-group-plc/register-investor)

Investors who already follow Venture Life Group plc on the Investor Meet
Company platform will automatically be invited.

 

For further information, please contact:

Venture Life Group PLC
 
+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cenkos Securities plc (Nomad and Joint Broker)
 
+44 (0) 20 7397 8900

Stephen Keys / Camilla Hume (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (https://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Active range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, products for fungal infections and proctology, and
dermo-cosmetics for addressing the signs of ageing. Its products are sold in
over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCXZLFBXKLBBBK

Recent news on Venture Life

See all news